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Abstract
Background: It is widely accepted that genetic variability might explain a large part of the observed heterogeneity
in aerobic capacity and its response to training. Significant associations between polymorphisms of different genes
with muscular strength, anaerobic phenotypes and body composition have been reported. Muscular
endophenotypes are positively correlated with aerobic capacity, therefore, we tested the association of
polymorphisms in twelve muscular related genes on aerobic capacity and its response to endurance training.
Methods: 935 Coronary artery disease patients (CAD) who performed an incremental exercise test until exhaustion
at baseline and after three months of training were included. Polymorphisms of the genes were detected using
the invader assay. Genotype-phenotype association analyses were performed using ANCOVA. Different models for a
genetic predisposition score (GPS) were constructed based on literature and own data and were related to
baseline and response VO2 scores.
Results: Carriers of the minor allele in the R23K polymorphism of the glucocorticoid receptor gene (GR) and the
ciliary neurotrophic factor gene (CNTF) had a significantly higher increase in peakVO2 after training (p < 0.05).
Carriers of the minor allele (C34T) in the adenosine monophosphate deaminase (AMPD1) gene had a significantly
lower relative increase (p < 0.05) in peakVO2. GPS of data driven models were significantly associated with the
increase in peakVO2 after training.
Conclusions: In CAD patients, suggestive associations were found in the GR, CNTF and the AMPD1 gene with an
improved change in aerobic capacity after three months of training. Additionally data driven models with a
genetic predisposition score (GPS) showed a significant predictive value for the increase in peakVO2.
Keywords: Cardiac Rehabilitation, Ischemic Heart Disease, Exercise Test, Physical capacity, genetic association, aero-
bic power
Background
In patients with ischemic heart disease aerobic power and
skeletal muscle strength are often reduced in comparison
with age and sex-matched healthy subjects [1]. Regular
physical activity improves aerobic power and skeletal mus-
cle strength and is accompanied with an increase in survi-
val in these patients. Moreover, aerobic power has been
shown to be an independent prognostic factor of survival
in patients with heart disease [2-4]. Therefore, participa-
tion in a cardiovascular exercise training program is
strongly recommended in coronary artery disease (CAD)
patients [5-7]. Recently, we reported an average increase
in aerobic power of 26% ± 22% (Standard Deviation; SD)
after a training period of three months in 1909 CAD
patients [8]. A considerable interindividual variation could
be observed with regard to aerobic power and its response
to physical training. We identified 12 independent deter-
minants, which accounted for 21% of the total variation in
the aerobic power response to three months of training
[8]. However, a large part of the individual variation
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twin studies showed that a large part (50 to 66%) of the
interindividual variation in aerobic power and its training
response can be explained by genetic factors [9-11]. Like-
wise, multivariate genetic analysis on muscle strength phe-
notypes indicated that additive genetic factors could
explain 66-78% of the variance in maximal elbow flexor
torque [12]. Dynamic resistance training programs induce
changes in muscle fibre size, fibre type and muscle meta-
bolism [13-16] which can lead to a greater oxygen uptake
by the muscle and a higher peak oxygen uptake (peakVO2)
[17]. Conley et al. [18] already pointed out that muscle
volume is an important determinant in the response of
peakVO2 to training. Therefore by increasing the amount
of muscle mass used in the various exercises, indepen-
dently of the mode of (resistance) training, the haemody-
namic responses become more dynamic (aerobic) in
nature. This was confirmed by Longhurst et al. [19] who
attributed the slight increase of peakVO2 in weight lifters
to the dynamic components in the exercises. In a subset of
80 CAD-patients we observed a significant increase (10-
15%) in muscle force after three months of cardiac rehabi-
litation [20]. In agreement with Kostka et al. [21] we
reported a correlation of r = 0.60 between baseline
peakVO2 and isometric and isokinetic muscle strength.
Further, a correlation of r = 0.32 between change in
peakVO2 and change in isometric muscle force could be
observed [20]. We therefore hypothesized that genes
encoding for the different muscular subsystems, e.g. mus-
cular structure, metabolism, cytokines, growth or differen-
tiation factors, neurotrophic factors and hormones might
be biologically plausible candidate genes that could be
involved in aerobic power variability and its response to
training. However, so far, research has mainly focussed on
the associations between polymorphisms of these various
genes and muscle strength, muscle function or their
response to training and not on the association with aero-
bic power [22,23].
We therefore aimed to identify whether previously
described polymorphisms in these genes account for dif-
ferences in aerobic power or its response to training in a
cohort of 935 cardiac patients included in the CAREGENE
study (CArdiac REhabilitation and GENetics of Exercise
performance and training effect). The significance of a
genetic predisposition score (GPS) for 7 literature based
replicated strength-related polymorphisms was tested in
predicting baseline aerobic power. Additionally, data dri-
ven models for GPS were tested in predicting baseline
aerobic power and the response of peakVO2 to training.
Methods
Study population
A detailed description of the CAREGENE study design,
eligibility criteria and methodology are presented
elsewhere [24]. In brief, 935 biologically unrelated Cau-
casian CAD patients (76 women; mean age 56 ± 0.3 yrs)
who had performed a graded cycle ergometer test until
exhaustion, before and after three months of physical
training, were included. The study protocol was
approved by the Ethical Committee of the Faculty of
Medicine of the Catholic University of Leuven and writ-
ten informed consent was obtained from each
participant.
Exercise training
Patients completed a three months ambulatory super-
vised exercise training program (90 minutes/session and
involving cycling, running, arm ergometry, rowing, pre-
dominantly isotonic calisthenics and relaxation). Train-
ing frequency averaged 2.27 ± 0.02 times/week and
training intensity was 79.7 ± 0.35% of the maximal heart
rate (HRmax). The latter was calculated as: (training
heart rate/peak heart rate) * 100, where the mean train-
ing heart rate of the last 3 exercise sessions and peak
heart rate of the exercise test after training were used.
Exercise testing
A detailed description of the exercise test methodology
has been reported previously [24]. Before and after the
three months training program patients completed a
maximal graded exercise test on a cycle ergometer with
respiratory gas analysis. The initial workload of 20 W
was increased until exhaustion by 30 W every 3 min
and after a protocol change in the year 2000 the initial
workload of 20 W was increased by 20 W per min.
Heart rate was measured throughout the test with a 12-
lead ECG and blood pressure was measured every 2
m i n u t e s .R e s p i r a t o r yd a t aw e r em e a s u r e dt h r o u g h
breath-by-breath analysis. PeakVO2 was defined as the
highest 15 seconds average of VO2 obtained at the end
of the test and was expressed as mL.min
-1. The percent
of predicted peakVO2 w a sc a l c u l a t e da sp e a k V O 2
divided by maximal predicted VO2,u s i n gt h ev a l u e s
reported by Wasserman et al. [25].
Genotype determinations
21 single nucleotide polymorphisms (SNPs) in 12 mus-
cular related genes were genotyped (Table 1). Selection
of genes and SNPs was based on a literature search at
the beginning of the study. SNPs had to be associated
with muscular phenotypes or aerobic phenotypes. DNA
was extracted from white blood cells using the ‘salting-
out’ method and the Invader TM assay (Third Wave
Technologies) was used for genotyping [26]. The Inva-
der assay combines structure-specific cleavage enzymes
and a universal fluorescent resonance energy transfer
(FRET) system. When the gene-specific probes bind the
target, these enzymes will cleave. This mechanism
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alleles, whereas the FRET system generates an amplified
readout [27]. In every experiment synthetic target oligo-
nucleotides were used as controls. Third Wave Technol-
ogies designed and provided all reaction components.
Genotyping was performed in a 96-well format. By com-
bining Probe mix (211 μl), Cleavase enzyme (79 μl)
FRET mix (317 μl) and MAP buffer (26 μl) the reaction
mixture was prepared. Of this mixture 6 mL was added
into a 96-well plate. Six micro litres of no target blank,
synthetic target oligonucleotides, or genomic DNA sam-
ples (50 ng/μl) were added. After short centrifugation
and incubation at 63°C for four hours, fluorescent inten-
sities were measured using a fluorescence microtiter
plate reader. By calculating the ratios of the net wild
type and net mutant (or minor allele) signals [28], geno-
types were determined. The analysis was repeated once
on those samples where no genotype could be obtained
during initial testing. Samples were excluded from the
analysis when genotyping failed twice (this failure rate
varies between 1.4% and 5.1%, data not shown).
Statistical methods
Data were analyzed using SAS statistical software
® ver-
sion 9.1 for Windows (SAS Institute Inc, Cary, NC,
USA). Data are reported as means ± SE or as number of
patients with percentage for dichotomous variables. To
test whether the observed genotype frequencies were in
Hardy-Weinberg equilibrium a c
2- test with one degree
of freedom was used. Distributions were checked for
normality with the Shapiro-Wilk statistic. Comparisons
between the exercise test at baseline and after training
were made by paired Student’s t-test; comparisons
across genotypes by AN(C)OVA, followed by Fisher’s
protected least significance difference (LSD) method if
significant. Where appropriate, categorical data were
tested by c
2 or by Fisher’s exact test. ANCOVA was
used with age, gender, stature, body mass and baseline
peakVO2 as covariates to test potential relationships
between gene variation and the increase in peakVO2
after training. Gene polymorphisms with a minor allele
frequency of less than 2% were analysed as carriers vs.
non-carriers of the minor allele.
Given the large set of gene variants and 3 phenotypes
under study, multiple testing issues probably induce
false positive interpretation of association findings. To
partially overcome the multiple testing problem and to
test for the additive effect of cumulative (response in)
VO2 uptake- alleles, a genetic predisposition score
(GPS) was calculated and its predictive value tested.
Based on recent literature, seven polymorphisms were
selected for this ‘increasing allele’ approach for baseline
peakVO2 [29-31]. Each of these polymorphisms has
been associated with muscle strength or function in at
Table 1 Overview of the investigated genes and polymorphisms within muscular structural or functional subsystems
Sub-System Gene Polymorphism Genotype frequency (n patients)
Metabolism adenosine monophosphate deaminase (AMPD1) C34T/rs17602729 CC (652) CT (239) TT (24)
Muscular structure Alpha-actinin 3 (ACTN3) Q523R/rs1671064 TT (303) TC (444) CC (176)
R577X/rs1815739 GG (468) GA (386) AA (66)
Myosine light chain kinase C49T/rs2700352 GG (589) AG (289) AA (38)
(MLCK) C37885A GG (749) GT (157) TT (9)
Cytokines Interleukin 6 (IL-6) G-174C/rs1800795 GG (332) GC (411) CC (176)
Interleukin 15 receptor PstI/rs2296135 CC (238) CA (468) AA (206)
alpha (IL-15Ra) BstNI/rs2228059 TT (223) GT (480) GG (211)
HpaII/rs3136618 GG (227) GA (459) AA (203)
Growth or differentiation factors Insulin-like growth factor 2 (IGF-II) ApaI/rs680 GG (448) AG (388) AA (80)
Activin-type II receptor B (ACVR2B) Rs2268757 TT (283) CT (468) CC (162)
Follistatin (FST) Rs3756498 CC (605) CT (278) TT (30)
Rs12152850 CC (606) CT (278) TT (35)
Rs12153205 TT (601) CT (275) CC (36)
v-akt murine thymoma viral oncogene homolog 1 (AKT1) G205T/rs1130214 GG (452) GT (377) TT (76)
Neurotrophic factors Ciliary Neurotrophic Factor (CNTF) G-6A/rs1800169 GG (664) GA (226) AA (21)
Ciliary Neurotrophic C-1703T/rs3808871 CC (580) CT (300) TT (41)
Factor Receptor (CNTFR) C174T CC (695) CT (187) TT (12)
Hormones Glucocorticoid Receptor R23K/rs6190 GG (857) GA (54) AA (1)
N363S/rs6195 AA (843) AG (70) GG (2)
BclI/rs41423247 CC (399) GC (403) GG (120)
Genotype frequencies (N) in the CAREGENE study included in brackets
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for the same increasing allele in all studies. The selected
polymorphisms were Alpha-actinin 3 (ACTN3 R577X),
Myosine light chain kinase (MLCK C49T), Insulin-like
growth factor 2 (IGF-II ApaI), Glucocorticoid receptor
(GR, R23K), Interleukin 15 receptor alpha (IL15Ra
BstnI), Ciliary Neurotrophic Factor Receptor (CNTFR C-
1703T and C174T). Additional file 1 shows which alleles
were chosen as the ‘increasing alleles’. An additive effect
was hypothesized and equal weights were given for each
increasing allele, because no well-defined effect sizes are
known for the different SNPs and weighting of increas-
ing alleles might only have limited effect [32]. The
genetic predisposition scores was calculated for each
individual by adding the strength-increasing alleles (0, 1
or 2) from all seven variants and was analyzed in a
GLM approach with age, gender, stature and body mass
as covariates. Additionally, based on our own data, back-
ward regression analysis was applied to detect three sub-
sets of SNPs to be associated with the three phenotypes;
baseline peakVO2, the simple difference (ml/min) in
peakVO2 ( m l / m i n )a n dt h er e l a t i v ed i f f e r e n c e( % )i n
peakVO2 after training. Based on these subsets of var-
iants we created three models to test the predictive
value of its GPS. Finally, when the predictive value of
the GPS was significant in the model, patients were
categorized in the upper 10% peakVO2 (High group)
and lower 10% peakVO2 (Low group) using sex-specific
cut-off scores. Similarly, high and low responder groups
were defined. Different logistic regression models were
used to test the power of the GPS to predict ‘high
group’ status, and to produce the receiver operating
characteristic curve (ROC curve) and the area under the
receiver operating characteristic curve (AUC). Predicted
probability was calculated for a hypothetical average
patient. Adjusted odds ratios were calculated to estimate
t h ee f f e c to ft h eG P Ss c o r ea st h eo d d sp e ri n c r e a s i n g
allele to belong to the high peakVO2 group or to the
high responder group. All statistical tests were per-
formed two-sided at a significance level of 5%.
Results
Descriptive characteristics of the overall study cohort (n =
935) are presented in Table 2. At baseline, overall aerobic
power averaged 1716 ± 16 mL.min
-1 or 77.9 ± 0.6% (± SE)
of the predicted normal value (men: 1766 ± 16 ml/min,
women: 1142 ± 31 ml/min, p < 0.0001). Three months of
physical training resulted in a significant average increase
of the aerobic power by 24.2 ± 0.6% (p < 0.001) (men: 24.1
± 17.4%, women: 25.1 ± 21.1, p = 0.47), ranging from a
decrease of 33.6% to an increase of 111.1%. Baseline
peakVO2 and its change after training follow the normal
Gaussian distribution (p > 0.05). At peak exercise, respira-
tory gas exchange ratio averaged 1.14 ± 0.003 at baseline
and 1.13 ± 0.002 after training (p > 0.05). Peak ventilatory
equivalent for oxygen was 38 ± 0.2 and 37 ± 0.2 respec-
tively (p > 0.05). None of the patient characteristics and
training characteristics were significantly different
amongst the different polymorphisms. c
2 tests revealed no
deviations from the Hardy-Weinberg equilibrium except
for G-174C of the IL-6 gene (p = 0.017).
Single polymorphism associations
Significant associations with the simple difference (ml/
min) and/or relative difference (%) in aerobic capacity
after three months of training could be observed for 3
out of the 21 investigated polymorphisms which were
genotyped (Table 3 and Additional file 2, Table S1).
In the R23K polymorphisms of the GR gene, carriers
of the minor allele had a significantly larger increase in
peakVO2, both in simple difference (ml/min) (p < 0.05)
and in relative (p < 0.05) term, compared to the homo-
zygous genotype groups. Further, homozygous CC geno-
type group members for the C34T polymorphism of the
AMPD1 gene showed a significantly larger relative
increase in peakVO2 compared to the carriers of the
minor allele (p < 0.05), whereas the increase in peakVO2
was significantly larger in the AA genotype group of the
G-6A polymorphism of the CNTF gene compared to the
homozygous GG group (p < 0.01).
Genetic predisposition score
A theoretical maximal GPS of 14 increasing alleles could
occur for seven selected polymorphisms based on recent
Table 2 Clinical characteristics for biologically unrelated
Caucasian CAD patients (n = 935) in the CAREGENE study
Variable Overall Cohort
N (%)
Women 76 (8)
Age (years) 56 ± 0.3
Body mass index (kg.m
-2) 25.8 ± 0.1
History of diabetes 49 (5)
History of hypertension 251 (27)
Current smoking 45 (5)
Past smoking 681 (73)
Complaints of angina pectoris in daily life 41 (4)
dyspnoea in daily life 149 (16)
AMI 630 (67)
-Anterior 252 (27)
-Inferior 333 (36)
CBS 377 (40)
PCI 470 (50)
Angina pectoris 23 (2)
AMI, acute myocardial infarction; CBS, coronary bypass surgery; PCI,
percutaneous coronary Intervention. Some patients had more than one
pathology. Data are presented as means ± SE for continuous variables and as
numbers (percentage) for dichotomous variables.
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polymorphisms. Figure 1 shows the distribution of GPS
within our patient group with four patients exhibiting
only one increasing allele up to six patients having nine
increasing alleles (max GPS = 9). To avoid the possibi-
lity of false positive results by the smaller groups at the
t w ot a i l s ,w ec o m b i n e dg r o u p s1a n d2a n dg r o u p s8
and 9. ANCOVA analysis showed no overall significant
differences between the patient groups categorized by
GPS scores and baseline peakVO2 (Figure 1) or simple
and relative difference in peakVO2 after training. How-
ever, based on linear regression (b = 13.5, p = 0.06) ana-
lysis, we observed a trend that higher numbers of
increasing alleles (higher GPS) result in a higher base-
line peakVO2.
Backward regression analyses revealed three subsets of
genes to be associated with baseline peakVO2 (ACTN3,
Q523R and GR, R23K), simple difference in peakVO2
(ACVR2B, rs2268757; CNTF, G-6A and GR, R23K) and
relative difference in peakVO2 (AMPD1, C34T;
ACVR2B, rs2268757; CNTF, G-6A and GR, R23K). Sig-
nificant differences were found in the models for simple
(p < 0.01) and relative difference (p < 0.001) in peakVO2
(Figure 2 and 3).
High vs. Low aerobic capacity groups
Additional analyses of the high vs. low responder groups
were performed for the GPS of the simple and relative
difference after training. In the model for simple differ-
ence in peakVO2, GPS alone was statistically significant
to predict a high increase in peakVO2 (AUC: 0.62; 95%
CI: 0.54-0.69, p < 0.01), (Odds ratio: 1.62; 95%CI: 1.13-
2.33) (Figure 4). In the model for relative increase in
peakVO2, GPS alone was also statistically significant to
predict a high relative increase in peakVO2 (AUC: 0.63;
95%CI: 0.56-0.71, p < 0.01), (Odds ratio: 1.68; 95%CI:
1.22-2.31) (Figure 5). Both models were comparable to a
model with age and weight to predict the simple and
relative difference in peakVO2 (AUC of 0.69 and 0.60
respectively). When GPS was added to the model with
age and weight, the predictive value increased with 2%
(simple difference) and 5% (relative difference). However
this increase in predictive value was not significantly dif-
ferent from the model with GPS alone or the model
with age and weight. Height and gender had no signifi-
cant contribution to the model and were omitted. A
patient with a high GPS has a higher probability to end
up in the group with the 10% highest increase in
peakVO2 values after training and vice versa. The GPS
had however no predictive value for the baseline
peakVO2 for both the literature based model as the
own-data model.
Table 3 Genotype-phenotype association analysis for muscular subsystem gene polymorphisms and baseline aerobic
power and changes after training in the CAREGENE study
Gene Polymorphism Allele Frequency VO2pre p-value VO2 change p-value VO2 change p-value
N (%) (ml/min)
a (ml/min)
b (%) b
AMPD1 C34T/rs17602729 CC 652 (71) 1711 ± 15 p = 0.40 396 ± 10 p = 0.11 24.8 ± 0.6 p = 0.04
CT + TT 263 (29) 1734 ± 23 367 ± 16 22.4 ± 0.99
CNTF G-6A/rs1800169 GG 664 (73) 1724 ± 15 p = 0.43 369 ± 9 p = 0.001 23.1 ± 0.6 p = 0.002
GA 226 (25) 1701 ± 25 416 ± 16 25.1 ± 1.0
AA 21 (2) 1801 ± 81 519 ± 52 33.9 ± 3.3
GR R23K/rs6190 GG 857 (94) 1715 ± 13 p = 0.08 383 ± 9 p = 0.02 23.8 ± 0.6 p = 0.04
GA + AA 55 (6) 1805 ± 50 464 ± 34* 28.5 ± 2.2*
AMPD1, Adenosine monophosphate deaminase; CNTF, Ciliary neurotrophic factor; GR, Glucocorticoid receptor
a. Mean ± SE, corrected for gender, age, height and weight;
b. Mean ± SE, corrected for gender, age, height, weight and baseline peakVO2
Figure 1 Genetic predisposition score for muscular subsystems
gene polymorphisms (literature based) and baseline peakVO2
in the CAREGENE study. Left Y-axis: Number of patients in each
increasing alleles group (bar graph). Right Y-axis: Baseline peakVO2
for each increasing alleles group (square dots ± SE) corrected for
age, gender, height and body mass. X-axis: GPS - Number of
increasing alleles. Regression line for baseline peakVO2
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associated with the change (ml/min) in peakVO2 in the
CAREGENE study. Left Y-axis: Number of patients in each
increasing alleles group (bar graph). Right Y-axis: Change in peakVO2
(ml/min) for each increasing alleles group (square dots ± SE)
corrected for age, gender, height, body mass, and baseline peakVO2.
X-axis: GPS - Number of increasing alleles. Regression line for the
change in peakVO2 (ml/min)
Figure 3 Genetic predisposition score for 4 polymorphisms
associated with relative change (%) in peakVO2 in the
CAREGENE study. Left Y-axis: Number of patients in each
increasing alleles group (bar graph). Right Y-axis: Relative change in
peakVO2 (%) for each increasing alleles group (square dots ± SE)
corrected for age, gender, height, body mass, and baseline peakVO2.
X-axis: GPS - Number of increasing alleles. Regression line for the
relative change in peakVO2
Figure 4 Overlay of three different models to predict high vs.
low responder in peakVO2 change (ml/min) after training.
Model GPS (AUC: 0.62; 95% CI: 0.54 - 0.69). Model age and weight
(AUC: 0.69; 95% CI: 0.61 - 0.77) Model GPS, age and weight (AUC:
0.71; 95% CI: 0.63 - 0.78)
Figure 5 Overlay of three different models to predict high vs.
low responder in relative peakVO2 change (%) after training.
Model GPS (AUC: 0.63; 95% CI: 0.56 - 0.71). Model age and weight
(AUC: 0.60; 95% CI: 0.52 - 0.69) Model GPS, age and weight (AUC:
0.65; 95% CI: 0.57 - 0.73)
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Since dynamic resistance training can induce changes in
muscle size, fiber type and muscle metabolism [13-16]
and can lead to a greater oxygen uptake, we hypothe-
sized that genes coding for these muscular subsystems
might also be involved in aerobic power or its change
after training through the different pathways of muscu-
lar endophenotypes (i.e. structure, growth factors, hor-
mones, ...). We found suggestive associations in
polymorphisms of the GR gene, AMPD1 gene and
CNTF gene with aerobic capacity or its change after
training in CAD patients.
Single polymorphism associations
GR
The mutation in codon 23 results in a change of argi-
nine to lysine. The mutation in R23K polymorphism,
which is a part of the ER22/23EK polymorphism com-
plex (as often described in the literature), has been asso-
ciated with a decreased glucocorticoid sensitivity which
can lead to decreased catabolism and less muscle atro-
phy [33-35]. Van Rossum et al. [36] showed that male
ER22/23EK-carriers had a higher muscle mass and
strength. In concordance with these results we found
that carriers of the minor allele of the R23K polymorph-
ism had a significantly higher increase in aerobic power
after three months of training. Although no significant
differences in peakVO2 were apparent at baseline, a ten-
dency could be observed that carriers of the minor allele
had a higher baseline peakVO2 (p = 0.08).
AMPD1
The C34T mutation results in a premature stop codon
of protein synthesis which is the main cause of AMPD
deficiency. Fishbein et al. [37] proposed that a deficiency
of AMPD causes muscular weakness or cramping after
exercise. Rico-Sanz et al. [38] showed that individuals
homozygous for the T allele in the C34T polymorphism
of the AMPD1 gene have diminished exercise capacity
and cardiorespiratory responses to exercise in the seden-
tary state and that the training response of ventilatory
phenotypes during maximal exercise is more limited in
TT. Due to the small number of individuals in the TT
homozygous group, we performed a combined CT + TT
vs. CC analysis. We showed that T allele carriers had a
significantly lower relative increase in peakVO2 after
three months of training compared to individuals homo-
zygous for the C allele (p < 0.05) which agrees with ear-
lier findings that the C34T mutation can lead to a
decreased exercise capacity and a lower response to
exercise (Rico-Sanz 2003).
CNTF
Circulating CNTF has trophic effects on neuronal and
muscular tissues. Earlier De Mars et al. [39] and Roth et
al. [40] hypothesized that, with regard to the CNTF G-
6A polymorphism, carriers of the minor allele would
have lower muscle strength than wild-type carriers due
to lower levels of circulating CNTF. However, both
research groups were unable to confirm their hypoth-
esis. Subsequently, Roth et al. [40] showed that indivi-
duals heterozygous for the G-6A polymorphism possess
significantly greater muscle strength and muscle quality
at relatively fast contraction speeds compared to homo-
zygous wild-type individuals.T h e r e f o r ei ti sp l a u s i b l e
that improved muscle strength and quality in these indi-
viduals may also result in a more pronounced increase
in aerobic power. We showed that A allele carriers of
the G-6A polymorphism had a larger increase in aerobic
capacity after three months of training (p < 0.01). The
homozygous minor allele group had almost 11% addi-
tional increase in peakVO2 after three months of train-
ing compared with the homozygous wild-type group. To
our knowledge, aerobic capacity has never been studied
in the G-6A polymorphisms of the CNTF g e n e ,s oi t
might be that individuals homozygous for the A allele
who exhibit higher muscle strength and quality at fast
contraction speeds [40] also have a higher aerobic capa-
city increase, measured on a bicycle treadmill. Unfortu-
nately we do not have muscle strength measurements in
this patient group so this hypothesis remains to be con-
firmed in additional studies.
Genetic predisposition score
To partially overcome the multiple testing problem and
to test for the additive effect of cumulative (response in)
VO2 uptake- alleles, an ‘increasing allele analysis’ is per-
formed, as was proposed by studies of Ruiz et al. [29],
Santiago et al. [30] and Williams et al. [31]. In calculat-
ing a genetic predisposition score (GPS) every poly-
morphism is considered to have an equal influence on
the phenotype, although weighting approaches have also
been taken [32]. Based on this hypothesis, every addi-
tional occurrence of a ‘beneficial’ allele for muscular
strength would result in an increased peakVO2. We con-
structed an ‘increasing allele analysis’ for baseline aero-
bic capacity with 7 polymorphisms, based on the
literature. Although no overall significant differences
between different allele groups were found, based on
linear regression (b = 13.5, p = 0.06) analysis, we
o b s e r v e dat r e n dt h a tah i g h e rG P Sr e s u l t si nah i g h e r
baseline peakVO2. An increase of peakVO2 by 13.5 ml/
min per allele equals approximately 1% increase in
peakVO2 with every additional increasing allele.
Based on backward regression analysis of the complete
group of polymorphisms, we identified three significant
subsets of polymorphisms associated with the three phe-
notypes; baseline peakVO2, simple and relative differ-
ence in peakVO2. The model for relative change showed
remarkable resemblance with the single polymorphism
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gene was not significantly associated in the single poly-
morphism associations). The GPS models for simple
and relative difference in peakVO2 showed significant
associations with the change in peakVO2 after training.
The GPS for the simple difference showed that patients
with a GPS of 0 had an increase of 335.3 ± 18.0 ml/min
whereas patients with a GPS of 2 or more would
increase with approximately 420 ml/min. The GPS for
t h er e l a t i v ec h a n g es h o w e ds i m i l a rr e s u l t s .G P So f1o r
less had an increase of 16.7% whereas patients with GPS
of 4 or more increased their peakVO2 with approxi-
mately 25%. The findings in both models were con-
firmed with an analysis of the 10% highest responders
versus the 10% lowest responders for both simple differ-
ence (ml/min) and relative difference (%) in peakVO2
after training. The odds ratio estimate for both models
showed that with every additional increasing allele, the
chance of belonging to the high responder peakVO2
g r o u pi s6 2 %a n d6 8 %h i g h e rf o rs i m p l ea n dr e l a t i v e
response respectively.
In conclusion, although we found some suggestive
associations between SNPs with aerobic capacity or its
improvement after three months of training, one should
carefully interpret the results. The CAREGENE study
population is not a random sample of the total popula-
tion, as they are all Caucasian CAD patients who had
been hospitalized before baseline testing (± 8 weeks
post-operation). These CAD patients who probably were
deconditioned by their disease have proceeded through
a spontaneous recovery which might also differ individu-
ally. Generalization is therefore limited. It might be that
our individuals are also genetically predisposed for CAD
and that this patient group might have distorted allele
frequencies for the genes under study. However allele
frequencies did not differ to the reported CEPH fre-
quencies in the HapMap database. One could speculate
that if the identified gene variants are not specifically
related to the CAD-status of the patients, and if under-
lying pathways that drive the adaptations do not differ
between CAD and healthy individuals, that these might
also play a role in exercise-induced changes in aerobic
capacity in healthy individuals.
Literature search at the beginning of the study led to a
selection of genes and polymorphisms in which associa-
tions were found with muscle structure or muscle func-
tion. We are aware that the field is evolving quickly and
‘new’ candidate gene variants have become available in
the mean time. We hypothesized that if patients had
better muscular performance by mutations of their
g e n e st h e ym i g h ta l s oh a v eab e t t e ra e r o b i cc a p a c i t yo r
the ability to improve more beneficially. This could be
generated by a better local oxygen extraction by the
muscles, which leads to a higher peakVO2. In a substudy
on 80 patients we found a correlation of r = 0.60
between baseline quadriceps isometric and isokinetic
muscle force and baseline peakVO2 and a correlation of
r = 0.32 between change in peakVO2 and change in iso-
metric muscle force [20]. Although these phenotypic
correlations have not been decomposed into genetic ver-
sus environmental covariation between the endurance
and strength phenotypes, they are however indicative for
at least partial pleiotrophic gene action. For more closely
related phenotypes e.g. walking speed and lower leg
power, substantial genetic correlations have been
reported [41]. Although we describe some pathways
within our associations, the lack of an objective mea-
surement of muscle force or function makes it hard to
confirm these hypotheses. In addition one could also
question if these genes for muscular structure and func-
tion are ‘good endophenotypes’ for improved peakVO2
as some studies have indicated that the ‘increasing allele’
for endurance is not necessarily the same as for maxi-
mal strength. With regard to genetic influence on aero-
bic capacity and/or its improvement after training, more
research is definitively needed with additional muscular
testing.
Furthermore we set the significance level at p < 0.05,
however when applying Bonferroni correction for multi-
ple testing none of our results would reach significance.
This study therefore also included a genotypic predispo-
sition score analysis, in which additive effects on seven
polymorphisms were studied, as well as a data-driven
GPS analysis was performed. Although meaningful phe-
notypic correlations between muscle strength and endur-
ance performance in this specific population do suggest
underlying pleiotrophic gene actions, the contribution of
each specific genetic variant is expected to be small.
Conclusion
Suggestive associations were found for changes in aero-
bic capacity and single polymorphisms of the CNTF,
AMPD1 and GR gene and a genetic predisposition score
showed a significant predictive value for this GPS to
estimate an individuals’ potential to belong to the higher
peakVO2 responder group, or inversely to predict the
risk of belonging to the low responder peakVO2 group.
Although no strong associations were found, it is rea-
sonable to assume that mutations in genes coding for
muscular structure and function can lead to changes in
aerobic capacity.
Additional material
Additional file 1: The selected increasing alleles for calculation of
the GPS score of the increasing allele analysis. For the ‘increasing
allele’ analysis a selection of 7 polymorphisms was made based on
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Page 8 of 10recent literature. The increasing allele is indicated here for each selected
polymorphism.
Additional file 2: Genotype-phenotype association analysis for
muscular subsystem gene polymorphisms and baseline aerobic
power and changes after training in the CAREGENE study (without
correction for baseline peakVO2). As we might be overcorrecting the
increase in peakVO2 by using baseline peak VO2 values as a covariate,
the results of Table 3 are shown here without correction for baseline
peakVO2.
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